Reconvalescent blood products, Passive vaccine
| PHA Serum products |
| 32361326 2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. |
32243945 ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection
32375025 ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32298745 ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
32226289 2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
32218340 2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
32254064 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19
32305026 ä. Challenges of Convalescent Plasma Therapy on COVID-19
32167489 ä. The convalescent sera option for containing COVID-19
32348485 ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
| 32249185 ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection |
32281317 2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
32219428 2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
32313872 ä. COVID-19 convalescent plasma transfusion
32113510 2020. Convalescent plasma as a potential therapy for COVID-19
C7158785 ä. Convalescent plasma: A possible treatment of COVID-19 in India
32343358 2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives
32253318 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients
32345485 ä. Treatment for emerging viruses: Convalescent plasma and COVID-19
32380316 ä. Convalescent plasma in Covid-19: Possible mechanisms of action
32359789 ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science
32359788 ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic
32217555 2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
| 32369628 2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |
32310190 2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
32356910 2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review
32293713 2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
32281679 2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy
32380316 2020. Convalescent plasma in Covid-19: Possible mechanisms of action
32324899 2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy
32319102 2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
32240545 2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
32374891 2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design
32374890 2020. COVID-19 convalescent plasma: phase 2
32219429 2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
32352484 2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19
| 32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development |
32281318 2020. Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying
32359447 2020. The resurgence of convalescent plasma therapy
| 32197324 2020. A Review on Applications of Computational Methods in Drug Screening and Design |
32407051 2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?
32512588 2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
32398379 2020. Convalescent plasma for patients with COVID-19.
32398378 2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.
32450629 2020. [Application of convalescent plasma therapy on novel coronavirus infection].
32437024 2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.
32444482 2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
32492105 2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.
32406927 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
32413374 2020. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.
32505474 2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.
| 32480418 2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients. |
32420691 2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
32453903 2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.
32453687 2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
32502707 2020. Convalescent plasma therapy in the treatment of COVID-19: Practical considerations: Correspondence.
32468508 2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.
32492084 2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
32473109 2020. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.
32525844 2020. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.
32425270 2020. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.
32405117 2020. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
32491199 2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.
32464700 2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.
32447783 2020. Convalescent plasma for COVID-19: Back to the future.
32449169 2020. How did we rapidly implement a convalescent plasma program?
32449171 2020. COVID-19: are neutralizing antibodies neutralizing enough?
32428966 2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.
32448638 2020. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
32417123 ä. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
| 32516462 2020. Anti-A Isohemagglutinin titers and SARS-CoV2 neutralization: implications for children and convalescent plasma selection. |
32438330 2020. Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases.
32425365 2020. Why should we use convalescent plasma for COVID-19?
32530454 2020. Convalescent Plasma and COVID-19.
32516839 2020. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.
32404189 2020. The role of passive immunization in the age of SARS-CoV-2: an update.
32526774 2020. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
32533868 2020. Guidance for the Procurement of COVID-19 Convalescent Plasma: Differences between High and Low-Middle Income Countries.
| 32533556 2020. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors. |
32473010 2020. Corrected idiotic title: Therapeutic Plasma Exchange–Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019 (TPE-nAbs)for severe COVID-19.
32527348 2020. [Effect of convalescent plasma and immunoglobulin on patients with severe acute respiratory syndrome: a systematic review].
32450171 2020. Coronaviruses pandemics: Can neutralizing antibodies help?
32533109 2020. Passive antibody therapy in COVID-19.
32404477 2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
32425645 2020. Use of convalescent plasma in COVID-19 patients in China.
32487513 2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
32532691 2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
32467007 2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.
32530808 2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.
32593060 2020. ...rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.
32236815 2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.
32573433 2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
| 32579067 2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies. |
32585194 2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.
32553190 2020. Appropriate selection of convalescent plasma donors for COVID-19.
32573724 2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.
32559767 2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.
32591393 2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
32566562 2020. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.
32542847 2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
32407543 2020. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.
32566896 2020. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
32413276 2020. Identification of Human Single-Domain Antibodies against SARS-CoV-2.
32426243 2020. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.
32531248 2020. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
32602952 2020. Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications.
32418917 2020. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
32593180 2020. Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery.
| 32536989 2020. IgY - turning the page toward passive immunization in COVID-19 infection (Review). |
32539093 2020. Monoclonal Antibodies for Prevention and Treatment of COVID-19.
32544372 2020. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.
32574267 2020. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
32593519 2020. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
32534509 2020. Management of COVID-19 Virus Infection by Convalescent Plasma.
32564002 2020. Az elso ket sikeres, convalescens friss fagyasztott plazmaval torteno terapia hazai alkalmazasa intenziv osztalyon kezelt, kritikus allapotu, COVID-19-fertozesben szenvedo betegekben: (A COVID-19-pandemia orvosszakmai kerdesei)
32214238 2020. How blood from coronavirus survivors might save lives.
32584322 2020. INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.
32563969 2020. Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
32561155 2020. Inmunoglobulinas por via intravenosa: una alternativa terapeutica a tener en cuenta en el paciente trasplantado renal con COVID-19.
32538591 2020. Convalescent plasma and covid-19 treatment.
32595357 2020. SARS-CoV-2 neutralizing antibody development strategies.
32571838 2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
32540904 2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
32540903 2020. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
32540902 2020. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
32540901 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
32540900 2020. Broad neutralization of SARS-related viruses by human monoclonal antibodies.
32560646 2020. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
32540345 2020. Anti-SARS-CoV-2 hyperimmune plasma workflow.
32563550 2020. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
32359090 2020. Convalescent plasma: possible therapy for novel coronavirus disease 2019.
